melanoma

Novartis announces EC approval for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for adjuvant treatment of BRAF V600 mutation-positive melanoma

Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III…

6 years ago

Roche phase III BRIM8 study: 46% reduction in recurrence risk was observed in stage IIC-IIIB melanoma patients

BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which…

7 years ago

Novartis: updated data from study shows significant overall survival benefit for patients with aggressive form of melanoma when treated with Tafinlar® + Mekinist®

Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar…

9 years ago